gsk & novartis, page-3

Sir Andrew Witty, Chief Executive Officer, GSK said:
“This proposed 3-part transaction accelerates our strategy to generate sustainable, broadly sourced sales growth and improve long-term earnings.

“Opportunities to build greater scale and combine high quality assets in Vaccines and Consumer Healthcare are scarce. With this transaction we will substantially strengthen two of our core businesses and create significant new options to increase value for shareholders.
“The Novartis OTC portfolio is highly complementary to GSK’s and has many well-known, widely recommended brands such as VOLTAREN, Excedrin, Otrivin, and Theraflu.

Thanks for posting GBR - I think this deal has significant relevance to OBJ.

FOR EXAMPLE: on a personal note - I would like to be able to take Voltaren, but can't as it upsets my stomach. But if down-the-track, I can slap on an VOLTAREN obj powered patch onto an inflamed ankle or wrist, I will do it in a heartbeat - and I would expect to be just one of millions around the world who would do so who can't take Voltaren currently.

And the beauty of this development - OBJ has already invested time and money into its Bodyguard patch - some of that expertise would no doubt be applicable to a VOLTAREN obj powered patch!